粪便和尿液代谢物而非肠道菌群或可预测肠易激综合征对低FODMAP饮食的应答
本研究将符合Rome III标准的肠易激综合征成人随机分为假饮食加安慰剂补充剂(对照)、低FODMAP饮食(LFD)加安慰剂或LFD加1.8 g/d β-半乳寡糖(LFD/B-GOS)三组,干预4周。第4周临床应答率分别为对照组30%(7/23)、LFD组50%(11/22)、LFD/B-GOS组67%(16/24),组间差异p=0.048。在LFD组中,基线粪便丙酸(敏感性91%、特异性89%)、环己烷羧酸酯(敏感性80%、特异性78%)及尿液代谢物谱(Q2 0.296 vs. 随机化 -0.175)可预测临床应答;对照组和LFD/B-GOS组中微生物群和代谢物未能区分应答者与无应答者。
要点
- LFD组4周临床应答率为50%(11/22),LFD/B-GOS组为67%(16/24),对照组为30%(7/23),组间p=0.048。
- LFD组基线粪便丙酸预测应答的敏感性91%、特异性89%,环己烷羧酸酯敏感性80%、特异性78%。
- LFD组尿液代谢物谱Q2 0.296 vs. 随机化 -0.175,可预测临床应答;对照组和LFD/B-GOS组中微生物群和代谢物未能区分应答者与无应答者。
核心结论
- 基线粪便和尿液代谢物或可预测肠易激综合征患者对低FODMAP饮食的应答。
研究设计与样本
- 研究招募符合Rome III标准的肠易激综合征成人,进行盲法随机对照试验,随机分为假饮食加安慰剂补充剂(对照)、LFD加安慰剂(LFD)或LFD加1.8 g/d β-半乳寡糖(LFD/B-GOS)三组,干预4周。
- 临床应答定义为干预4周后症状充分缓解(整体症状问题);分析应答者与无应答者间粪便微生物群(FISH、16S rRNA测序)及粪便(气液色谱、气相色谱-质谱)和尿液(1H NMR)代谢物的差异。
主要发现
- 4周时三组临床应答率分别为对照组30%(7/23)、LFD组50%(11/22)、LFD/B-GOS组67%(16/24),组间差异p=0.048。
- 在LFD组,基线粪便丙酸(敏感性91%、特异性89%)、环己烷羧酸酯(敏感性80%、特异性78%)及尿液代谢物谱(Q2 0.296 vs. 随机化 -0.175)预测临床应答。
- 在对照组和LFD/B-GOS组,微生物群和代谢物未能区分应答者与无应答者。
关键数值与推荐
- LFD组基线粪便丙酸预测应答的敏感性91%、特异性89%。
- LFD组基线粪便环己烷羧酸酯预测应答的敏感性80%、特异性78%。
- LFD组尿液代谢物谱Q2 0.296 vs. 随机化 -0.175。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The low FODMAP diet (LFD) leads to clinical response in 50%-80% of patients with irritable bowel syndrome (IBS). It is unclear why only some patients respond. AIMS: To determine if differences in baseline faecal microbiota or faecal and urine metabolite profiles may separate clinical responders to the diet from non-responders allowing predictive algorithms to be proposed. METHODS: We recruited adults fulfilling Rome III criteria for IBS to a blinded randomised controlled trial. Patients were randomised to sham diet with a placebo supplement (control) or LFD supplemented with either placebo (LFD) or 1.8 g/d B-galactooligosaccharide (LFD/B-GOS), for 4 weeks. Clinical response was defined as adequate symptom relief at 4 weeks after the intervention (global symptom question). Differences between responders and non-responders in faecal microbiota (FISH, 16S rRNA sequencing) and faecal (gas-liquid chromatography, gas-chromatography mass-spectrometry) and urine (1 H NMR) metabolites were analysed. RESULTS: At 4 weeks, clinical response differed across the 3groups with adequate symptom relief of 30% (7/23) in controls, 50% (11/22) in the LFD group and 67% (16/24) in the LFD/B-GOS group (p = 0.048). In the control and the LFD/B-GOS groups, microbiota and metabolites did not separate responders from non-responders. In the LFD group, higher baseline faecal propionate (sensitivity 91%, specificity 89%) and cyclohexanecarboxylic acid esters (sensitivity 80%, specificity 78%), and urine metabolite profile (Q2 0.296 vs. randomised -0.175) predicted clinical response. CONCLUSIONS: Baseline faecal and urine metabolites may predict response to the LFD.
引用
- Wilson B, Kanno T, Slater R, et al. Faecal and urine metabolites, but not gut microbiota, may predict response to low FODMAP diet in irritable bowel syndrome. Aliment Pharmacol Ther. 2023. PMID: 37313992. doi:10.1111/apt.17609
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。